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1. Introduction 
The cells throughout the human body are constantly subjected to both internal forces and 
external insults that cause damage to their DNA. This damage to the DNA can be harmful to 
the overall integrity of the cell and the ability for replication. Accurate transmission of 
genetic information from one cell to its progeny is dependent upon mechanisms within the 
cell to monitor any defects within its genome and to repair these deficiencies so as not to 
pass them to subsequent generations. These mechanisms are mainly mediated through an 
array of DNA damage response proteins including DNA damage sensors, signal 
transducers and effectors. Sensors, such as ATM (ataxia telangiectasia mutated) and ATR 
(ATM-Rad3-related), have the ability to recognize areas of damage and activate signal 
transducers, which either activate or inactivate effectors. Effector proteins trigger cell cycle 
checkpoint and the cell may successfully repair the damage or proceed towards apoptosis if 
these damages are irreparable. These molecules are not only necessary for surveillance of 
occasional non-lethal DNA damage, but are also important for the survival of the cell and 
the organism. Moreover, mutations to these DNA damage response proteins may contribute 
to an unstable genome and the development of cancer.  
In this chapter we will briefly review the cell cycle and relevant checkpoint proteins. We will 
also discuss in detail the DNA damage response signal transduction pathway and 
associated proteins: ATM, ATR, ChK1, Chk2, p53, BRCA-1, PARP-1, and BRIT-1,. Finally, 
we will discuss the future strategy in targeting the defects of these proteins in the treatment 
of breast cancer.  
Key Words: DNA Damage Response, ATM, ATR, p53, BRCA-1, BRIT-1, PARP-1, PARP 
inhibitors, Triple Negative Breast Cancer 
2. The cell cycle: A brief overview 
The cell cycle, first described in 1979, has been accepted as the central dogma of cell 
replication and contains two main phases; Interphase and the Mitotic phase (Fig. 1.) 
The G1 (Gap 1) phase of the cycle is the period in which the cell may grow and function 
normally. New proteins are synthesized and organelles that the daughter cells will need are 
created. The synthesis or S phase of the cell cycle follows the G1 phase and is the period of 
the cell cycle in which the genetic material of the cell is replicated. As stated before, accurate 
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DNA replication is needed to prevent genetic aberrations that may lead to cell death. The 
regulatory pathways and proteins that govern this event are highly conserved in eukaryotic 
cells. 
 
 
Fig. 1. The Cell Cycle 
The G1/S phase transition is a major checkpoint in the cell cycle. The checkpoint response to 
DNA damage at the G1 phase is mediated by the ATM(ATR)/Chk2(Chk1)—p53/MDM1-p21 
pathway, which will be discussed later in this chapter. Expression of ATM and Chk2 are 
relatively constant during the cell cycle while the concentrations of ATR and Chk1 increase 
closer to the G1/S transition (Kastan & Bartek, 2004). The end of the G1 Phase consists of the 
induction of Cyclin E and A, and CDC25A phosphatase, the activator of Cyclin E (A)/CDK2 
kinase. In the event of DNA damage, Chk1 down-regulates CDC25A and in effect inhibits 
Cyclin E (A)/CDK2 kinase which stalls the transition from G1 to S. During the S phase of the 
cell cycle as the genome is replicated, intra S phase checkpoint networks can also be activated 
as a result of genotoxic insult. The two parallel branches of this checkpoint, controlled by the 
ATM/ATR signaling mechanism, will also be further discussed in the chapter.  
Arguably, the most important phase of the cell cycle is the Synthesis and G2 phases. The G2 
phase of interphase is the second growth period as the cell prepares for mitosis. Using a 
large number of highly conserved proteins, the G2/M checkpoint prevents cells from 
entering the mitosis should they experience DNA damage after the S phase, or if they 
should progress through G1-S-G2 with damage having occurred in previous phases that 
had been heretofore unrepaired (Kuntz & O’Connell, 2009). All forms of DNA damage, as 
well as incomplete replication, activate the checkpoint. The mitosis promoting Cyclin 
B/CDK1 kinase activity is a critical target of the G2 checkpoint. Cyclin B/CDK1 kinase is 
inhibited by the actions of ATM(ATR)/Chk2(Chk1) and/or p38 kinase mediated subcellular 
sequestration, degradation and inhibition of CDC25 family of phosphatases that normally 
activate CDK1 (Kastan & Bartek, 2004). The G2 checkpoint also relies on checkpoint 
mediators BRCA-1 and p53 which lead to the upregulation of cell cycle inhibitors p21 and 
GADD45a.  
The G0 (Gap zero) phase of the cell cycle in which the cells enter a quiescent state. It can be 
viewed as an extended G1 phase or as a separate phase outside of the cell cycle. It is separate 
from apoptosis or senescence in that the cell is metabolically active may enter the G1 phase 
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and carry out the rest of the replicative cell cycle if needed. Should the cell complete 
interphase and not be ushered towards G0 or apoptosis the cell is allowed to enter the much 
shorter Mitotic phase consisting of Prophase, Metaphase, Anaphase and Telophase, the 
details of which will not be discussed in this chapter.  
3. DNA damage 
Sources of DNA damage may be endogenous or environmental. Reactive oxygen and 
nitrogen compounds are produced by macrophages and neutrophils at sites of inflammation 
and infection. These reactive species can attack DNA which leads to adducts that impair 
baseparing and/or block DNA replication and transcription, base loss, or cause DNA single 
strand breaks. Spontaneous alterations in DNA base chemistry and errors in the replication 
of DNA in the S phase may also contribute to endogenous DNA damage. The most 
pervasive environmental DNA-damaging agent is ultraviolet radiation. Ultraviolet A and B 
in strong sunlight can induce ~100,000 lesions per exposed cell per hour (Jackson & Bartek, 
2009). Ionizing radiation can also generate various forms of DNA damage, and double 
strand DNA breaks (DSBs). Most environmental carcinogens operate by generating DNA 
damage and causing mutation. DSBs can also form in a programmed manner during 
development including meiosis (germ cell generation) and immunoglobin rearrangement.  
DNA strand breaks occur after topoisomerase activity is aborted. Topoisomerase I and II are 
enzymes that unwind and wind DNA to control the synthesis of proteins and facilitate 
replication and damage repair. This action is targeted by chemotherapies such as Etoposide, 
which works by forming a complex with the Topoisomerase II enzyme preventing the re-
ligation of the DNA Strands causing errors in DNA synthesis and promotes cell apoptosis.  
DNA Mismatches occur via physiological processes such as DNA replication and are strand 
specific. They are recognized by DNA Mismatch repair proteins MSH1 and MLH2 and 
when theses proteins are deficient or mutated this may lead to micro satellite instability as 
seen in hereditary nonpolyposis colorectal cancers and Muir-Torre Syndrome.  
4. DNA damage repair 
A complex network of proteins and enzymes are designated to detect, signal the presence of, 
and repair DNA damage. This highly conserved DNA Damage Repair (DDR) signal 
transduction pathway (figure 2.) allows the cell to survive and maintain the integrity of the 
genome prior to replication or directs a cell with an overwhelming number of genomic 
defects towards apoptosis.  
4.1 Non Homologous End Joining and Homologous Recombination 
Non Homologous End Joining (NHEJ) seen in the repair of DSBs that are induced by 
radiation. Double strand breaks are recognized by the Ku protein, which then binds to and 
activates the protein kinase DNA pKcs. This leads to the recruitment and activation of end 
processing enzymes, polymerases, and DNA Ligase IV. While this mechanism is error 
prone, it has the advantage of the ability to occur in any phase of the cell cycle. Homologous 
recombination (HR) results in fewer errors as it uses sister chromatid sequences as the 
template to mediate faithful repair. HR is initiated by DSBs, stalled replication forks and 
single strand DNA (ssDNA), and is restricted to the S and G2 phases of the cell cycle. Single 
strand DNA recruited by RAD51, BRCA-1 and BRCA-2 invades the damaged DNA 
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template. DNA ligation occurs with nucleases, polymerases, and helicases. HR restart 
stalled replication forks and requires Fanconi Anemia Protein complex (FANC) to repair 
interstrand DNA crosslinks. 
 
 
Fig. 2. The DNA Damage Response 
4.2 The role of ATM and ATR  
Two phosphatidylinositide-3-related kinases, Ataxia telangiectasia mutated (ATM) and 
ATM-rad3 related (ATR), are sensors integral to the DNA damage response. Their 
recruitment to DNA lesions is highly conserved and is required for PIKK-dependent DNA 
damage signalling (Falck et al., 2005). ATM responds to double strand breaks created by 
ionizing radiation, controlling the initial phosphorylation of several proteins including p53, 
Mdm2, BRCA-1, Chk2 and Nbs1. While ATR responds to stalled replication forks, ssDNA 
and DNA damage induced by UV damage. ATR also diminishes the G2/M checkpoint 
response induced by -radiation (Zhou & Elledge, 2000). 
ATM and ATR are recruited to and activated by DSBs and replication protein A (RPA) 
coated ssDNA. ATM-ATR complexes with DNA dependent protein kinases, which 
phosphorylate Serine 139 on H2AX, a histone variant. Phosphorylated H2AX is referred to 
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as H2Ax and recruits DDR factors and relaxes the chromatin actively marking the sites of 
DNA damage. The resulting immunostainable nuclear foci dubbed IRIFs (irradiation-
induced foci) serve as a platform where checkpoint and DNA repair proteins accumulate to 
promote propagation of the damage signals and repair (Peng & Lin, 2008). 
Effector protein kinases, Chk1 and Chk2, are the most understood targets of ATM and ATR 
respectively. They are serine/threonine kinases that are structurally unrelated but share 
overlapping substrate specificity (Zhou & Elledge, 2000). Chk2 is the homologue of yeast 
Rad53 and Cds1, and is phosphorylated in response to ionizing radiation in an ATR 
dependent fashion. Chk1 is phosphorylated on Ser 345 in response to hydroxyurea and 
ultraviolet light. The complex of ATM/ATR and Chk1/Chk2 leads to the reduction of Cyclin 
Dependent Kinases which, as previously described, slows/arrests the cell cycle at G1-S, intra S 
and G2-M check points, allowing for time to repair the damaged DNA prior to replication 
(Jackson & Bartek, 2009; Falck et al. 2001; Zhou & Elledge, 2000). Mutations of Chk2 alleles in 
irradiated cells are unable to undergo phosphorylation and fail to inhibit DNA synthesis after 
damage, making Chk2 a candidate tumor suppressor (Falck et al., 2001). 
ATM and ATR also enhance DDR repair by inducing the DNA-repair proteins by 
modulating their phosphorylation, acetylation, ubiqutylation or SUMOylation (Jackson & 
Bartek, 2009). After cell cycle arrest, if the DSB gets repaired via NHEJ or HR, the DDR is 
inactivated and the cell is able to complete mitosis. If the DNA is unable to be repaired, 
chronic DDR signaling triggers cell death by apoptosis or cellular senescence.  
4.3 p53 
TP53 is a tumor suppressor gene that is known as the custodian of the genome. Ironically, it 
is also the most frequently mutated gene in human cancer. The p53 gene encodes a nuclear 
phosphoprotein that normally activates G1 cell cycle arrest in response to DNA damage 
(Fan et al. 1995). This arrest extends the time available before S phase entry. Cells with 
mutant p53 fail to arrest in G1, but rather accumulate in the G2 phase. P53 can also activate 
an apoptotic response to DNA damage, especially in hematopoetic and lymphoid cells. In 
breast carcinomas, 15-40% of tumors present an altered TP53 gene and are associated with 
aggressive disease and poor overall survival. Although p53 mutations are less frequent in 
hormone expressing tumors, the prognostic value of TP53 function is relevant in 
determining the patient’s response to chemotherapy. 
Focal adhesion kinase, FAK/PTK, is a tyrosine kinase that is over expressed in a variety of 
human cancers. FAK is a regulator of adhesion and motility and its upregulation is 
associated with increased metastatic potential. FAK has been shown to contain p53 
responsive elements that are down regulated by DNA damage in a p53 dependent manner. 
When p53 is defective in estrogen receptor positive breast cancer cell lines, loss of FAK 
down-regulation is associated with increased proliferation and invasion when these cells are 
exposed to estradiol (Anaganti, 2011). This suggests that the loss of p53 function not only 
promotes tumorigenesis but also contributes to the metastatic potential of estrogen-
responsive tumors.  
4.4 BRCA-1 and BRCA-2  
The breast cancer genes, BRCA-1 and BRCA-2, encode a nuclear phosphoprotein that acts as 
a tumor suppressor and plays a role in maintaining genomic stability and are located on 
chromosome 17 and 13 respectively. The BRCA-1 gene was identified in 1994 as a cause of 
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hereditary breast cancer and has since been shown to function in the complex HR pathway 
of DNA repair. The encoded protein combines with other tumor suppressors, DNA damage 
sensors, and signal transducers to form a large multi-subunit protein complex known as the 
BRCA-1-associated genome surveillance complex (BASC). BRCA-1 promotes cell cycle arrest 
with p53 and associates with DSBs marked by RAD51 foci. ATM and BRCA-2 gather with 
BRCA-1 and RAD51 at the sites of double-strand DNA damage. BRCA-2 does not seem to 
play as important a role in the cell cycle checkpoint responses to DNA damage as BRCA-1, 
however it has been implicated in the mitotic spindle checkpoint, homologous 
recombination, and chromatin remodeling.  
Mutations in breast cancer genes are responsible for approximately 40% of sporadic breast 
cancers and more than 80% of inherited breast and ovarian cancers. In the case of BRCA-1 
and BRCA-2, heterozygous BRCA-1 mutation carriers have a high lifetime risk of breast and 
ovarian cancer, and patients with a BRCA-2 mutation will also have a high lifetime risk, 
though with later onset. The majority of pathogenic BRCA-1 and BRCA-2 mutations are 
small insertions, deletions or nonsense mutations that result in premature stop codons and a 
shortened, non-functional BRCA protein.  
Women carrying a heterozygous deleterious mutation in the BRCA-1 gene carry a 57% 
cumulative risk of developing breast cancer by the age of 70 years and a 40% risk of 
developing ovarian cancer (Annunziata & Bates, 2010). In cells lacking functional BRCA-1 or 
BRCA-2, HR is deficient and DDR may proceed through more error-prone NHEJ. This, 
when applied with a PARP inhibitor, may lead to further propagation of DNA damage and 
the death of the cell as will be detailed below. It is unclear why breast or ovarian epithelial 
cells are more susceptible to the oncogenic outcome of BRCA deficiency. 
4.5 PARP-1 and PARP inhibitors 
Poly (ADP-Ribose) polymerase is an abundant nuclear protein and is a key regulator of base 
excision repair process. PARP1 detects single strand breaks arising from reactive oxygen  
species and is also involved in the repair of DSBs. The poly ADP ribose activates histones, 
transcription factors, and signalers (NFkB, DNAPk, Laminin B) and has an N-terminal DNA 
binding domain that contains two zinc fingers, which bind to both SSBs and DSBs. PARP 
activates itself to recruit other component of SSB repair. When PARP-1 is inhibited, normal 
cells proceed towards homologous recombination repair of the DNA damage. As stated 
above, when BRCA-1 and BRCA-2 is mutated, cells are unable to proceed towards HR. 
When PARP-inhibitors are applied, the cell cannot repair the DNA damage and becomes 
apoptotic, leaving the normal cells unaffected (Liang et al. 2009) as seen in figure 3. This 
inhibition of PARP-1 also sensitizes tumor cells to chemotherapy and radiation in vitro. 
Currently, clinical trails are being conducted to assess the efficacy of PARP-1 inhibitors, such 
as Olaparib, in the treatment of patients with breast and ovarian cancer with BRCA-
1/BRCA-2 mutations and triple negative receptor breast cancers (Annunziata & Bates, 2010).  
4.6 BRIT-1  
The BRCT-Repeat Inhibitor or hTET expression/Microcephalin or BRIT-1 gene is located on 
chromosome 8 (8p23.1) and is a damage response protein that is physically recruited to sites 
of damaged DNA. The most distinct role of BRIT-1 is to stop the G2-M transition in the cell 
cycle of damaged cells. ATM and ATR act on BRIT, However, BRIT is NOT required to 
phosphorylate ATM but is needed to recruit pATM to the damaged DNA and also 
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positively regulates CHK1 and BRCA-1 expression. BRIT binds to chromatin and forms 
nuclear foci after exposure to ionizing radiation or UV rays as short as 2 minutes after the 
radiation occurs (Chaplet et al., 2006). This chromosome region is frequently deleted in 
breast, ovarian and prostate cancers. Microarray data from a public database show that 
BRIT1 mRNA levels are markedly decreased in 19 of 30 cases; 63% of ovarian cancer 
specimens relative benign ovarian tissue specimens and 72% or the 54 breast cancer cell 
lines tested also showed a decrease in the BRIT1 gene copy number (Lin et al. 2010).  
 
 
Fig. 3. Action of PARP–inhibitors in HR deficient cells. 
When wild type and BRIT knock down cells are irradiated, BRIT deficient cells continue to 
enter mitosis at a greater rate than the wild types cells (Chaplet et al., 2006). This supposes 
that the DNA damage that was created during irradiation is not being sufficiently repaired 
in the BRIT1- group and thus genome mutations are propagated through subsequent 
generations. BRIT1 has also been clearly demonstrated to be crucial for maintaining genomic 
stability in vivo. Using gene targeting technology to create BRIT1 knock out mice, the BRIT-/-
mice were able to survive to adulthood but they were growth retarded and hypersensitive 
to IR when compared to wild type and heterozygous mice (Liang et al., 2010). Our data 
suggest that breast tumors can be induced in the mammary glands of mice with conditional 
BRIT1 deficiency via irradiation, but not in the control littermates. BRIT knock down cells 
also show reduced expression of BRCA-1 and Chk1 (Lin et al. 2005). The next step will be to 
investigate if, and to what extent, BRIT1 deficiency may contribute to the initiation and 
progression of cancer with the existence of oncogenic or genotoxic stress.  
5. DNA damage repair and triple negative breast cancer 
5.1 Breast cancer epidemiology  
Breast cancer is the most common female malignancy and second to lung cancer in terms of 
mortality. It is the leading cause of death among women aged 40 to 50 years. According to 
the Surveillance Epidemiology and End Results (SEER) Program of the National Cancer 
Institute, based on rates from 2005-2007, 12.15% of women born in the United States today 
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will be diagnosed with cancer of the breast at some time during their lifetime. The estimated 
new cases of breast cancer in 2010 were 207,090 (female); 1,970 (male) and deaths were 
39,840 (female); 390 (male) (Altekruse et al., 2010). The SEER data also show that from 2003-
2007, the median age at diagnosis for cancer of the breast was 61 years of age with 0.0% were 
diagnosed under age 20; 1.9% between 20 and 34; 10.5% between 35 and 44; 22.6% between 
45 and 54; 24.1% between 55 and 64; 19.5% between 65 and 74; 15.8% between 75 and 84; and 
5.6% 85+ years of age The age-adjusted incidence rate was 122.9 per 100,000 women per 
year. These rates are based on cases diagnosed in 2003-2007 from 17 SEER geographic areas. 
(Altekruse et al., 2010). 
5.2 Breast cancer risk factors  
The most important risk factor for the development of breast cancer is gender with the 
female to male ratio being 100:1. Further risk factors for breast cancer and relative risks as 
elegantly described by Singletary in 2003 are shown in table 1. A personal history of breast 
cancer is a significant risk factor for the development of contralateral breast cancer with an 
incidence of 0.5%-1.0% per year. As stated previously in the chapter, exposure to ionizing 
radiation, such as for the treatment of Hodgkin’s Lymphoma, has been associated with an 
increased risk of breast cancer, especially if it occurs prior to age 30, however the risk is less 
in the first 15 years after treatment than after 15 years (Zager et al, 2006).  
 
Risk Factors Category at Risk Relative Risk 
Alcohol Intake 2 drinks per Day 1.2 
Body Mass Index 80th percentile, age 55 or older 1.2 
Hormone replacement 
therapy with estrogen AND 
progesterone 
Current user for at least 5 
Years 
1.3 
Ionizing radiation exposure 
Treatment for Hodgkin’s 
Disease 
5.2 
Age at first Childbirth 
Nulliparous or 1st Child after 
30 
1.7-1.9 
Current age 65 or older 5.8 
Past History of Breast Cancer Invasive Breast Cancer 6.8 
Family History 
First Degree relative with 
premenopausal breast cancer
3.3 
First Degree relative with 
postmenopausal breast cancer
1.8 
Germline Mutation 
Heterozygous for BRCA1  
age <40 
200 
Heterozygous for BRCA1  
age 60-69 
15 
Table 1. Risk Factors for Breast cancer (Singletary, 2003). 
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Breast diseases such as adenosis, fibroadenomas, apocrine changes, duct ectasias and mild 
hyperplasias carry no increased risk for breast cancer as they are non-proliferative. 
However, proliferative diseases, such as atypical ductal or lobular hyperplasias do carry an 
increased risk. Hormone replacement therapy used for the treatment of postmenopausal 
symptoms have been shown to increase a woman’s risk of developing breast cancer, yet 
patients may weigh this risk with the benefits of hormone therapy such as a decrease in 
postmenopausal symptoms and increased bone density.  
The age of the patient is also a risk factor for breast cancer. For women who experience 
menopause after the age of 55 the risk of breast cancer is twice that of women who enter 
menopause before age 44. Women who experience regular ovulatory cycles prior to age 13 
have a 4 fold increased risk of breast cancer than women who had up to a 5 year delay in the 
development of regular cycles. Women who menstruate for more than 30 years are also at a 
greater risk for developing breast cancer than women who menstruate for less than 30 years 
(Zager et al. 2006).  
Family history of breast cancer is very important in determining the risk of breast and other 
cancers. Though the majority of breast cancers are of the sporadic type, the highest risk is seen 
in patients with a young (premenopausal) first-degree relative with bilateral breast cancer 
(Zager et al. 2006). Overall risk is determined by the number of relatives with cancer, their ages 
at diagnosis and laterality of their disease (unilateral or bilateral). The above risk factors have 
been used in the Gail breast cancer risk model, which will be discussed later in this chapter.  
Genetic abnormalities have also been seen to predispose individuals to breast and ovarian 
cancers. Autosomal dominant mutations such as Li-fraumeni syndrome, Muir-torre 
Syndrome and, of course, BRCA-1 and BRCA-2 mutations which predispose patients to 
breast cancer have been well described and are diagrammed in table 2. As seen in the 
previous table, heterozygosity for BRAC-1 germline mutation carries a relative risk of 200 
for the development of breast cancer.  
 
Syndrome Site of Mutation Increased Malignancies of: 
BRCA-1 Chromosome 17q 
Breast, Ovarian, 
Prostate, Colon 
BRCA-2 Chromosome 13q 
Breast (including male), Ovaries, 
Prostate, larynx, pancreas 
Li- Fraumeni 
p53 gene on 
chromosome 17p 
Breast, brain, adrenal glands, soft 
tissue sarcomas 
Muir-Torre 
DNA Mismatch repair genes 
hMLH1 and hMSH2 on 
chromosome 2p 
Breast, gastrointestinal tract, 
genitourinary tract, sebaceous 
tumors, keratoacanthomas 
Cowden Disease 
PTEN gene on 
chromosome 10q 
Breast, Colon, Uterus, thyroid, 
lung, bladder. Hamartomatous 
polyps in the GI tract. 
Peutz-Jegers 
STK11 gene on 
chromosome 19p 
Breast, Pancreas, mucocutaneous 
melanin deposition 
Hamartomatous polyps in the GI 
tract. 
Table 2. Autosomal dominant mutations and syndromes associated with increased risk for 
breast cancer (Zager et al, 2006). 
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5.3 Luminal and basal sub-typing  
Breast cancers are often described in terms of luminal and basal subtypes corresponding to 
their likely origin based on hormone receptor status. The luminal subtypes A and B are 
characterized by estrogen receptor (ER+) expression and expression of genes associated 
with luminal epithelial cells. Luminal A tumors are often low grade while luminal B tumors 
are often high grade. Human epidermal growth factor Receptor 2 receptor positive tumors 
(also known as HER2/neu or ERBB2) encode a member of the epidermal growth factor 
(EGF) receptor family of receptor tyrosine kinases. These tumors respond to trastuzumab, a 
monoclonal antibody that binds to the domain IV of the extracellular segment of the 
HER2/neu receptor causing arrest during the G1 phase of the cell cycle. While the HER2 
phenotype is aggressive, this response to trastuzumab makes for a favorable prognosis.  
The basal-like subtype is characterized by the expression of basal keratins 5 and 17, laminin 
and fatty acid binding protein 7. Large portions of basal subtype tumors are also lacking 
expression of ER, Progesterone Receptor (PR) and HER2. These tumors are termed triple 
negative breast cancer due to their lack of the three receptors (Jaspers et al. 2009).  
5.4 Triple negative breast cancer  
Triple negative breast cancers (TNBC) show the poorest survival of all US groups and are 
larger than and show a higher rate of node positivity at the time of diagnosis. Triple 
negative breast cancers have a high prevalence in young, obese women; and pre-
menopausal African-American women, compared to post menopausal African-American 
and non-African-American women. They also present as interval cancer with a weak 
association between tumor size and lymph node involvement. TNBCs have a high risk of 
early recurrence with a peak recurrence rate seen between the first and third years after 
diagnosis with metastasis rarely preceded by local recurrence and most mortalities 
occurring in within the first 5 years, further highlighting the need for close clinical follow-up 
(Chacón & Constanzo, 2010). 
Like basal subtype tumors, TNBC patients have significantly higher rates of pathological 
complete response following neoadjuvant chemotherapy, with increased frequency of distant 
metastasis formation but not local relapse (Jaspers et al. 2009). The majority of BRCA-1-related 
breast tumors share phenotypic features with TNBCs and basal- like tumors as they mostly 
lack expression of ER and HER2, and have epidermal growth factor over-expression and p53 
mutations. These similarities suggest that basal-like breast cancers arise through common 
genetic pathways as BRCA-1 mutated cancers. Recently, an unselected cohort of patients with 
TNBC was found to have a 19.5% incidence of BRCA mutations with 12.6% in BRCA-1 and 
3.9% in BRCA-2 (Gonzalez-Angulo et al., 2011). This suggests that TNBC and basal- like breast 
cancers may be similar to BRCA-1 mutated tumors in their pathogenesis and that they may be 
susceptible to PARP-1 inhibitors and other chemotoxins that are designed for BRCA-1 mutated 
tumors. These findings also suggest that genetic counseling may be indicated in patients 
presenting with triple receptor negative breast cancer.  
6. Targeting DNA damage repair defects in the treatment of breast cancer 
6.1 Development of new treatment modalities 
For patients with breast cancer, treatment consists of surgery, radiation, hormonal and 
chemotherapy. Commonly, clinicians employ a combination of all of these modalities to 
prevent loco-regional recurrence or to treat distant metastasis. Radiation and some 
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chemotherapeutics rely on the inherent DDR impairment of tumor cells to induce apoptosis. 
Cancer cells, which proliferate more rapidly than most normal cells, are thought to be 
especially vulnerable DNA damage exposure, which occurs during S phase of the cell cycle. 
Chemotherapeutics that induce DDR inhibition might enhance the effectiveness of 
radiotherapies and DNA damaging chemotherapies. 
The status of DNA damage repair proteins may also allow for the prediction of breast cancer 
sensitivity to neoadjuvant chemotherapy. In a recently published study (Asakawa et al. 
2010) sixty patients with primary breast invasive ductal carcinoma consecutively underwent 
neoadjuvant chemotherapy with Epirubicin and Cyclophosphamide (EC), two 
chemotherapies that induce DSBs, followed by treatment with docetaxel. The investigators 
were able to correlate focus formation of BRCA-1, H2AX, and RAD51 prior to treatment 
and RAD51 focus formation after treatment with mean tumor volume reduction and tumor 
response rate. When cells showed a high percentage of DDR nuclear foci staining shortly 
after the first EC treatment, they showed poor tumor response when evaluated for mean 
tumor volume reduction, which, in breast cancer, is a major goal of neoadjuvant 
chemotherapy. These findings may lead to the possibility of using DDR status clinically to 
determine which patients will respond to chemotherapy. 
Targeting specific DDR proteins to inhibit is another way to develop tailored treatment 
modalities. As stated prior in the case of PARP-1 inhibitors, breast and ovarian cancer 
patients with BRCA-1 and BRCA-2 mutations may be more likely to respond favorably than 
those patients with functioning BRCA-1. This could be a great breakthrough for these 
patients as they generally have more aggressive disease with high rates of loco-regional 
recurrence, elevated risk of contralateral breast cancer formation and are notoriously 
resistant to the chemotherapeutics available today. We can further these efforts to 
investigate patients with deficiencies in other DDR associated proteins.  
DDR targeted cancer therapies currently in clinical trails include those targeting the Chk1 
and Chk2 proteins. The inherent resistance to radiation of cancer stem cells is another 
challenge to overcome and inhibiting the Chk1 auto phosphorylation may increase the 
toxicity of DNA damaging agents that are currently in use and may improve 
radiosensitvity. In the case of p53, which is functionally reduced in 50% of cancers, efforts 
have been made to restore the wild type p53 activity via recombinant adenovirus encoding 
p53 or by using small compounds and short peptides to restore the function. (Bolderson et 
al. 2009) 
6.2 Development of new cancer screening modalities and risk assessments 
As stated previously, women who have BRCA-1 germline mutations have a higher risk of 
developing breast cancer than the general population, and the cancer that they develop is 
exceedingly aggressive with a high rate of recurrence, development of contralateral disease 
and resistance to current chemotherapies. Genetic testing is now being used to identify 
patients with the genetic predispositions to develop tumors. This testing allows clinicians to 
better define a patient’s effective risk and to allow for preventive treatment strategies such 
as prophylactic surgery or hormonal therapies. In the case of multiple family members 
presenting with breast cancer, genetic counseling should be offered to the patient affected 
with the disease first to determine what type of mutation is being expressed before testing 
any unaffected relatives for the disease. In the case of BRCA-1 and BRCA-2 mutation 
screening, commonly used methods their advantages and disadvantages were described in 
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the 2006 paper by Palma and is reproduced here in table 3. These methods include: Direct 
Sequencing (DS); Single Strand Conformation Polymorphism Analysis (SSCA); 
Heteroduplex Analysis (HAD); Denaturing Gradient Gel Electrophoresis (DGGE); Chemical 
Cleavage Mismatch (CCM); Protein Truncation Test (PTT); and Denaturing High 
Performance Liquid Chromatography (DHPLC).  
 
Technique Principle for Detection Advantages/Disadvantages 
DS Direct sequencing of DNA 
fragments 
Best sensitivity ~100%, Exact location and 
nature of deletion .  
Labor intensive and expensive 
DHPLC Detects heteroduplex through 
their chromographic elution 
profiles 
High sensitivity  
≤ 100%, rapid and precise  
Initial investment in equipment is high. 
However, low cost single analysis 
PTT Detects pre-terminal in vitro 
synthesized protein products 
98% sensitive, gives approximate location of 
pathogenetic mutations in large fragments.  
Only detects sequence alterations 
responsible for truncated proteins. Cannot 
analyze small exons.  
CCM Detects heteroduplex through 
chemical cleavage at the site of 
DNA mismatch 
Good sensitivity (>95%) 
Scans large fragments. Approximates 
location of damage.  
Time consuming and labor intensive.  
DGGE Altered Electrophilic mobility 
of heteroduplex based on their 
melting behavior (denaturing) 
Rapid and easy after initial planning.  
Low detection rate. Difficult to set up 
technique. 
HAD Altered Electrophilic mobility 
of heteroduplex (non-
denaturing)  
Rapid and easy to carry out, Detects 
insertion/deletion mutations in large 
fragments.  
Low detection rate (80%) poor for point 
mutations 
SSCA Altered Electrophilic mobility 
of single stranded DNA 
Rapid and easy to carry out 
Low detection rate (70-80%) scans short 
fragments.  
Table 3. Commonly used methods for BRCA1 / 2 mutational screening in descending order 
of sensitivity. (Palma et al., 2006)  
In the interpretation of these genetic tests, patients who test negative and have a known 
affected relative who is positive for a specific mutation are thought of as “real negatives” 
and have a risk of that of the general population. “Non informative” tests are from patients 
who test negative but who do not have a previously identified familial BRCA-1 or BRCA-2 
alteration. There may be a mutation in another gene or a low penetrance gene. The 
subsequent treatment of family members who test positive for a BRCA-1 or BRCA-2 
mutation depends on the age of the patient and the desire of child bearing. Prophylactic 
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bilateral mastectomies reduce the risk of breast cancer by up to 90%, and while the risk of 
ovarian cancer is lower than the risk for breast cancer in the context of BRCA mutation, the 
absence of early detection screening for ovarian cancer has increased the necessity for 
prophylactic oophorectomy (Palma et al., 2006).  
DNA damage repair protein function may be another useful tool to incorporate into our 
risk stratification models. The Gail Breast Cancer Risk Assessment model has been in use 
since 1989 (Gail, et al. 1989). This model, adopted by the National Cancer Institute, uses 
individual risk factors of age; family breast cancer history (amongst first degree relatives); 
age of first menarche and first live birth; personal medical history including number of 
previous breast biopsies and confirmed atypical hyperplasia; and race. A 5-year risk 
estimate and lifetime risk are calculated via logistic regression of the risk factors and 
converted into absolute risk based on epidemiological data for breast cancer incidence 
and other risks. A Gail 5-year risk score greater than or equal to 1.66% has been seen to be 
an important tool to identify women who have an increased risk for developing breast 
cancer.  
This method is not without shortcomings, including having a lower sensitivity for women of 
color, having been based on a cohort of Caucasian women, and has been challenged in the 
use of patients younger than age 40 (MacKarem et al., 2001). However when these clinical 
features of the Gail model are combined with genetic information they may increase the 
power of the test. Single-nucleotide polymorphisms (SNPs) are reproducibly associated with 
breast cancer risk in women of European and other racial or ethnic backgrounds. 
Investigators located seven SNPs associated with breast cancer risk from the literature and 
genotyped in white non-Hispanic women in a nested case- control cohort of 1664 case 
patients and 1636 control patients within the Women’s Health Initiative Clinical Trail. SNP 
risk scores were calculated and combined with Gail risk estimates. These investigators 
found that the SNP risk score was nearly independent of Gail risk with good agreement 
between predicted and observed SNP relative risks. Combining validated genetic risks 
factors with clinical risk factors modestly improved classification of breast cancer risk in 
these women (Mealiffe et al., 2010). This may be able to be extrapolated to other genetic 
mutations further combining what we know to be absolute clinical risk factors with DNA 
damage repair gene germline mutations to create a more inclusive model for the prediction 
of breast cancer development.  
7. Conclusion 
The cells throughout the human body are constantly subjected to both internal forces and 
external insults that cause damage to their DNA. Understanding the DNA damage response 
pathway is key to the understanding breast cancer tumorigenesis and to the creation of 
superior chemotherapeutics.  
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